The inhibition of BRD4 and SMAD3 through BETi or genomic editing can be valuable therapeutic strategies to exploit the anti-tumor potential of NK cells in adoptive NK/CAR-NK cell therapies or, alternatively, to rescue/enhance autologous NK activity in TME of NSCLC patients. This evidence concerns the gene SMAD3 and neoplasm.